



**CONF-711115**

**PROCEEDINGS OF SEMINAR ON THE USE OF STABLE  
ISOTOPES IN CLINICAL PHARMACOLOGY,  
UNIV. OF CHICAGO, NOVEMBER 10-11, 1971**

August 1972

The University of Chicago  
Chicago, Illinois

Argonne National Laboratory  
Argonne, Illinois

and

Los Alamos Scientific Laboratory  
Los Alamos, New Mexico

PROCEEDINGS OF A SEMINAR  
ON THE USE OF STABLE ISOTOPES  
IN CLINICAL PHARMACOLOGY

November 10-11, 1971

The University of Chicago  
Center for Continuing Education

Edited by Peter D. Klein and Lloyd J. Roth

Editorial Coordination

S. V. Peterson

Editorial Secretary

D. M. Purdy

Co-sponsored by

The University of Chicago  
Argonne National Laboratory

and

Los Alamos Scientific Laboratory

and supported in part by the National Science Foundation  
and the NICMS of the National Institutes of Health

PROCEEDINGS OF A SEMINAR  
ON THE USE OF STABLE ISOTOPES  
IN CLINICAL PHARMACOLOGY

**Organizing Committee**

**Lloyd J. Roth, Chairman**

**Peter D. Klein**

**Eugene S. Robinson**

**Bert N. Tolbert**



These Proceedings are dedicated  
to

Eugene Sant Robinson

May 31, 1916 - June 22, 1972



Biemann



Berlin



Bush



DeGrazia



Fales



Freese



Gaffney



Goldstein



Hofmann



M. C. Horning



Kipnis  
iv



Klein



Lester



Matwiyoff



Morgan



Nyhan



Ott



Robinson



Roth



Tolbert



Wall



Watson



Weiger



## CONTENTS

### Introduction

Lloyd J. Roth . . . . .	1
-------------------------	---

### SESSION I

#### Production of Stable Isotopes

E. S. Robinson . . . . .	5
--------------------------	---

#### Organic Synthesis and Biosynthesis

Donald G. Ott . . . . .	15
-------------------------	----

### SESSION II

#### Validation and Comparison of Deuterium/Tritium and Carbon-13/ Carbon-14 in Clinical Studies of Bile Acid Metabolism

Alan F. Hofmann, Rudy G. Danzinger and Neville E. Hoffmann . . . . .	37
Peter D. Klein, Otto W. Berngruber, and Patricia A. Szczepanik . . . . .	

#### The Use of Isotopic Tracers in the Study of Genetic Disorders of Metabolism in Children

William L. Nyhan . . . . .	53
----------------------------	----

#### Radiorespirometry Studies of the Effects of L-Dopa and MK486 Therapy--A Model Application of Carbon Isotopes to the *In Vivo* Evaluation of Intermediary Metabolism During Clinical Drug Trials

J. A. DeGrazia and M. R. MacLaury . . . . .	71
---	----

### SESSION III

#### The Measurement of Isotope Ratios in Organic Molecules by Mass Spectroscopy

Peter D. Klein . . . . .	101
--------------------------	-----

#### A $^{13}\text{C}$ Experiment Using Mass Spectrometer Breath Analysis

B. B. McInteer . . . . .	132
--------------------------	-----

#### An *In Vivo* Study of the Metabolism of Human Plasma

Glycosphingolipids Using 6,6 Dideuterioglucose as a Tracer Dennis E. Vance and Charles C. Sweeley . . . . .	141
--	-----



## SESSION IV

Nuclear Magnetic Resonance	
N. A. Matwiyoff . . . . .	153
Some Applications of $^{13}\text{C}$ NMR to Biological Problems, Past and Future	
Charles T. Gregg . . . . .	175

## SESSION V

Wednesday Evening Session	
General Discussion - Toxicology	
B. N. Tolbert . . . . .	191

## SESSION VI

Application of Stable Isotopes to Studies in Reproductive Biology	
Uwe E. Freese . . . . .	213
Perinatal Bile Acid Metabolism	
Roger Lester . . . . .	219

## SESSION VII

Labeling with $^{15}\text{N}$ or $^{13}\text{C}$ for Identification of Mass Spectra of Drugs and Their Metabolites	
M. T. Bush, H. J. Sekerke, Jr., M. Vore, B. J. Sweetman and J. T. Watson . . . . .	233
The Use of Multiple Ion Detection in Drug Metabolism Methodology	
J. Throck Watson . . . . .	239
Use of Stable Isotopes in Pharmacology - Clinical Pharmacology	
Daniel R. Knapp and Thomas E. Gaffney . . . . .	249
Coding of Barbiturate Sources by Stable Isotope Labeling During Manufacture	
Mark A. Minton and Peter D. Klein . . . . .	265
An Analog Multiplexer for Multiple Specific Ion Detection in a Gas Chromatograph/Quadrupole Mass Spectrometer System	
Donald J. Jenden and Robert W. Silverman . . . . .	273
<u>Concluding Remarks</u>	
Lloyd J. Roth . . . . .	291
List of Participants . . . . .	293
Author Index . . . . .	296

## INTRODUCTION

Lloyd J. Roth  
Department of Pharmacology  
University of Chicago, Chicago, Illinois

Welcome to the Seminar on the Use of Stable Isotopes in Clinical Pharmacology.

This meeting, organized by Peter Klein, Eugene Robinson, Bert Tolbert, and myself, grew out of a National Symposium on Carbon 13 held at Los Alamos on June 9-11, 1971 which was concerned largely with physical and analytical measurements. At that time it became apparent that a second meeting concerned with biological applications was desirable because the availability of stable isotopes would soon make possible many studies in the human which heretofore could be carried out only with radioactive tracers.

There is no doubt that the introduction of stable isotopes in clinical research will open a new era not unlike that which followed the distribution of radioactive isotopes on a commercial scale two decades ago.

The group here assembled is a heterogeneous one. Everyone is an expert in some area, but lacking expertise in another. Thus, in the best of all possible worlds, each will be able to participate in both the teaching and the learning process. It is in this spirit that we expect this gathering to provide the basis for a continuing dialogue between the participants long after this short contact.

Dr. Robinson's paper will open the meeting. It is a great pleasure for me to introduce him, because Robbie and I were graduate students in chemistry at Columbia University so long ago it is hard to remember. We went in divergent paths, and to come together at this meeting is a personal, if not a slightly emotional, experience for me.



## CHEMICAL RESOURCES

Chairman: L. J. Roth

### PRODUCTION OF STABLE ISOTOPES

*E. S. Robinson*

### ORGANIC SYNTHESIS AND BIOSYNTHESIS

*D. G. Ott*



## PRODUCTION OF STABLE ISOTOPES

Eugene S. Robinson  
Chemistry and Nuclear Chemistry-4  
Los Alamos Scientific Laboratory, Los Alamos, New Mexico

One thing that we at Los Alamos have discovered about isotopes is that if they are essentially free, or cheap, people will do experiments with them. If isotopes are kept at high prices, you may buy a gram at \$1,000.00, but it sits on the shelf waiting for the definitive experiment, and no real use is made of it.

Stable isotopes are now being produced at the Los Alamos Scientific Laboratory due to the efforts of Dr. B. B. McInteer and his associates. The techniques they use involve cryogenic distillation of liquid carbon monoxide and liquid nitric oxide.

A typical system as developed by Dr. McInteer is shown in Figure 1. The carbon monoxide plant is in three sections, a single column of 80 feet for the enriching section at the bottom, a combination of 4 columns about 20 feet long, and an upper section of 12 columns 40 feet long, so that there is a total of some 140 feet in the entire plant. It has a production rate of about 4 kg per year, and the feed rates are given in Figure 1. Input is 3020 liters a day which produces about 20 liters a day of enriched material.

In new production facilities now under construction, the unit will be 720 feet high and will include nitric oxide columns.

The NO plants are somewhat more complicated (Figure 2) because  $^{17}\text{O}$  must be separated from both  $^{16}\text{O}$  and  $^{18}\text{O}$ ; also  $^{14}\text{N}$  and  $^{15}\text{N}$  are both present. A number of different combinations of columns is required. I am just giving you a rough idea of what the production facilities are like. A handout which gives much more detail about what is going on at Los Alamos is available (Los Alamos Scientific Laboratory Report, LA-4391).

What we are doing now and plan to do is probably more interesting to you.

TABLE I

ICONS PRODUCTION

	<u>kg/yr</u>	
	<u>Now</u>	<u>1974</u>
$^{12}\text{C}$	9	156
$^{13}\text{C}$	9	50
$^{14}\text{N}$	180	2600
$^{15}\text{N}$	0.7	10
$^{16}\text{O}$	200	3000
$^{17}\text{O}$	0.08	1.1
$^{18}\text{O}$	0.47	6.8

With such large amounts of stuff available you may wonder what we are going to do with all of it. I think I can give you a rough idea.

Some of the uses of these isotopes are shown in Table II.

TABLE II

USES

1. SNAP REACTORS
2. HEART PUMPS
3. HEART PACERS
4.  $^{17}\text{O}$  CHEMICAL RESEARCH via. N.M.R.
5.  $^{15}\text{N}$  HEAVY ION ACCELERATORS
6.  $^{13}\text{C}$  CHEMICAL RESEARCH - N.M.R.
7.  $^{13}\text{C}$  WILL REVOLUTIONIZE BIOLOGY, BIOCHEMISTRY, AND CLINICAL MEDICINE.

$^{16}\text{O}$  is being used in SNAP reactors. Those are power reactors in which the heat produced by alpha particles is used. If human beings are working near them one must worry about the neutron background from ( $\alpha, n$ ) reactions, so they make  $^{238}\text{Pu}$  oxide with  $^{16}\text{O}$  which has as low a background as the metal itself. It is also used in heart pump experiments as a power source, as well as in heart pacers.

Essentially all of the  $^{17}\text{O}$  is used at Los Alamos for NMR in physical, inorganic, and organic chemistry research. No  $^{17}\text{O}$  from this source is available outside the laboratory.  $^{15}\text{N}$  and  $^{18}\text{O}$  are used in chemical research, but they are also used in heavy ion accelerators because they are rich in neutrons.  $^{12}\text{C}$ , not listed in the table, will be used for beam dumps and making mechanical parts for accelerators. It has very low cross-sections for many accelerator reactions.

$^{13}\text{C}$  is used in chemical research. We also think that because carbon forms the backbone of all organic molecules, it will cause a little revolution in biochemical and medical research.

TABLE III

SOME DISEASES THAT MAY BE DIAGNOSED  
BY A SIMPLE ORAL FEEDING OF A SPECIAL COMPOUND OF  $^{13}\text{C}$   
AND A BREATH ANALYSIS FOR  $^{13}\text{CO}_2$

EARLY DIABETES  
THYROID DISEASE  
THIAMINE DEFICIENCY  
STEATORRHEA  
FOLIC ACID DEFICIENCY, ANEMIAS  
RADIATION SICKNESS  
HYPER-ADRENAL GLUCOCORTICOIDISM  
PELLAGRA  
DIVERTICULITIS  
TROPICAL SPRUE  
MALABSORPTION SYNDROME  
HYPERLIPEMIAS  
GOUT OR HYPERURICEMIA  
ARTEROSCLEROSIS  
HEART DISEASE

Table III was compiled by Dr. Walton Shreeve from Brookhaven National Laboratory. He suggests a group of diseases that may be diagnosed by simple oral feeding and breath analysis for  $^{13}\text{C}$  dioxide. In fact, there is a cooperative experiment on the diagnosis of early diabetes among Los Alamos Scientific Laboratory, Brookhaven National Laboratory, and the Argonne National Laboratory, in which Dr. Peter Klein is taking part.

With these isotopes available in large quantities, it is desirable to have simple and convenient schemes for detection. Such methodology is all-important for you who need to use them for diagnostic purposes or for tracing. Methods that are available to you, or at least some of them, are presented in Table IV.



TABLE IV

METHODS OF DETECTION

MASS SPECTROSCOPY - MOST SENSITIVE AND GENERAL

METHOD. DIFFICULT WITH COMPLICATED MOLECULES.

NUCLEAR MAGNETIC RESONANCE - ODD NUCLEI  $^{13}\text{C}$ ,

$^{15}\text{N}$ , and  $^{33}\text{S}$  CAN "SEE" THE ENVIRONMENT OF THE  
ATOM IN A COMPLEX MOLECULE.

VIBRATIONAL SPECTROSCOPY - SIMPLE MOLECULES,  
INFRARED AND RAMAN SPECTROSCOPY.

ROTATIONAL SPECTRA - SIMPLE MOLECULES, INTER-  
FEROMETER + FOURIER TRANSFORM

Mass spectrometry is one of the most sensitive and general methods. However, for very complex molecules it is a lot of work to get the information out in usable form.

Nuclear magnetic resonance, a newer technique, offers the advantage that you can actually see the site of the  $^{13}\text{C}$  so that structures may be obtained, which is more difficult by other techniques. In mass spectrometry the site of  $^{13}\text{C}$  incorporation must be found by degradation of the molecule. The odd nuclei, such as  $^{17}\text{O}$ ,  $^{13}\text{C}$ ,  $^{15}\text{N}$ , and  $^{33}\text{S}$ , are active in nuclear magnetic resonance.

The disadvantage of nuclear magnetic resonance is that one needs at least  $10^{20}$  magnetic nuclei in a sample of about 2 ml, so that it requires more material than does mass spectrometry. In experiments with human beings, they being large animals, a large sample may be taken; microscopic amounts are not involved unless you are interested in substances of very low abundance.

Vibrational spectroscopy can also be used, but the sensitivity is somewhat lower. Isotope ratios may be determined to about 1.5%. In some cases, the infrared spectrometer may be capable of doing breath analyses for  $^{13}\text{C}$  in  $\text{CO}_2$ .

H. A. Gebbe, from the Bureau of Standards at Boulder, Colorado, has developed very sensitive rotational spectrometric techniques. Samples must be converted to something that has a good rotational spectrum. Carbon dioxide will probably have to be reduced with zinc dust to carbon monoxide in order to get a decent measurement.

A type of measurement not listed in Table IV uses reactions that can be carried out at institutions where accelerators are available. Reactions like the  $^{13}\text{C}$  (p, $\gamma$ ) and  $^{12}\text{C}$  (p, $\gamma$ ) may be exploited. These are extremely sensitive. Isotope ratios may be obtained with as little as  $10^{-9}$  grams of material.